Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tejaswini Kulkarni

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Respiratory Research|January 8, 2022
Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO RegistryJoao A de Andrade, Tejaswini Kulkarni, Megan L Neely, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|June 14, 2015
Heme oxygenase-1-mediated autophagy protects against pulmonary endothelial cell death and development of emphysema in cadmium-treated miceRanu Surolia, Suman Karki, Hyunki Kim, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 30, 2017
Autoimmunity to Vimentin Is Associated with Outcomes of Patients with Idiopathic Pulmonary FibrosisFu Jun Li, Ranu Surolia, Huashi Li, et al.
Annals of the American Thoracic Society|October 9, 2014
Characteristics of patients with pulmonary venoocclusive disease awaiting transplantationKeith M Wille, Nirmal S Sharma, Tejaswini Kulkarni, et al.
Plos One|November 23, 2021
Correlates of survival after autoantibody reduction therapy for acute IPF exacerbationsTejaswini Kulkarni, Vincent G Valentine, Fei Fei, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|October 4, 2016
Attenuated heme oxygenase-1 responses predispose the elderly to pulmonary nontuberculous mycobacterial infectionsRanu Surolia, Suman Karki, Zheng Wang, et al.
Plos One|April 4, 2015
Heme oxygenase-1 protects corexit 9500A-induced respiratory epithelial injury across speciesFu Jun Li, Ryan N Duggal, Octavio M Oliva, et al.
American Journal of Respiratory and Critical Care Medicine|May 5, 2026
Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled TrialToby M Maher, Mark J Hamblin, Won-Ii Choi, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Inhaled LTI-03 for Idiopathic Pulmonary Fibrosis: A Randomized Dose Escalation StudyPhilip L Molyneaux, Nikhil A Hirani, Collin C K Chia, et al.
Clinical and Experimental Rheumatology|February 25, 2026
Shaping the landscape of interstitial lung disease in idiopathic inflammatory myopathies: state of the art, evidence gaps and a need for clinical trialsDaphne Rivero Gallegos, Faye M Pais, Ting-Yuan Lan, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Respiratory Research|January 8, 2022
Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO RegistryJoao A de Andrade, Tejaswini Kulkarni, Megan L Neely, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|June 14, 2015
Heme oxygenase-1-mediated autophagy protects against pulmonary endothelial cell death and development of emphysema in cadmium-treated miceRanu Surolia, Suman Karki, Hyunki Kim, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 30, 2017
Autoimmunity to Vimentin Is Associated with Outcomes of Patients with Idiopathic Pulmonary FibrosisFu Jun Li, Ranu Surolia, Huashi Li, et al.
Annals of the American Thoracic Society|October 9, 2014
Characteristics of patients with pulmonary venoocclusive disease awaiting transplantationKeith M Wille, Nirmal S Sharma, Tejaswini Kulkarni, et al.
Plos One|November 23, 2021
Correlates of survival after autoantibody reduction therapy for acute IPF exacerbationsTejaswini Kulkarni, Vincent G Valentine, Fei Fei, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|October 4, 2016
Attenuated heme oxygenase-1 responses predispose the elderly to pulmonary nontuberculous mycobacterial infectionsRanu Surolia, Suman Karki, Zheng Wang, et al.
Plos One|April 4, 2015
Heme oxygenase-1 protects corexit 9500A-induced respiratory epithelial injury across speciesFu Jun Li, Ryan N Duggal, Octavio M Oliva, et al.
American Journal of Respiratory and Critical Care Medicine|May 5, 2026
Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled TrialToby M Maher, Mark J Hamblin, Won-Ii Choi, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Inhaled LTI-03 for Idiopathic Pulmonary Fibrosis: A Randomized Dose Escalation StudyPhilip L Molyneaux, Nikhil A Hirani, Collin C K Chia, et al.
Clinical and Experimental Rheumatology|February 25, 2026
Shaping the landscape of interstitial lung disease in idiopathic inflammatory myopathies: state of the art, evidence gaps and a need for clinical trialsDaphne Rivero Gallegos, Faye M Pais, Ting-Yuan Lan, et al.
Pageof 5